Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 6 (2009), Issue 10 (October)

  1. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.
    J Nucl Med, 50(10): 1585-93. [Abstract] [Full-text]
  2. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.
    J Nucl Med, 50(10): 1709-14. [Abstract] [Full-text]
  3. Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2.
    J Cell Physiol, 221(3): 771-7. [Abstract] [Full-text]
  4. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
    Lancet Oncol, 10(10): 981-91. [Abstract] [Full-text]
  5. Health-related quality of life evaluation in patients undergoing cavernous nerve reconstruction during radical prostatectomy.
    Jpn J Clin Oncol, 39(10): 671-6. [Abstract] [Full-text]
  6. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.
    Oncogene, 28(39): 3487-98. [Abstract] [Full-text]
  7. Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
    J Immunol, 183(8): 4848-52. [Abstract] [Full-text]
  8. Study of robustness of IMPT and IMRT for prostate cancer against organ movement.
    Int J Radiat Oncol Biol Phys, 75(3): 941-9. [Abstract] [Full-text]
  9. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.
    Cancer Cell, 16(4): 336-46. [Abstract] [Full-text]
  10. Percutaneous fluoroscopically guided salvage of misplaced perirectal (125)I prostate seeds-easy way out.
    Urology, 74(4): 924-5. [Abstract] [Full-text]
  11. Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis.
    Urology, 74(4): 884-8. [Abstract] [Full-text]
  12. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.
    Urology, 74(4): 866-71. [Abstract] [Full-text]
  13. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
    Urology, 74(4): 878-83. [Abstract] [Full-text]
  14. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Urology, 74(4): 873-7. [Abstract] [Full-text]
  15. Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis.
    Exp Cell Res, 315(17): 3004-13. [Abstract] [Full-text]
  16. Erectile function durability following permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 75(3): 639-48. [Abstract] [Full-text]
  17. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Int J Radiat Oncol Biol Phys, 75(3): 656-63. [Abstract] [Full-text]
  18. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.
    Int J Radiat Oncol Biol Phys, 75(3): 649-55. [Abstract] [Full-text]
  19. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
    Int J Cancer, 125(11): 2528-39. [Abstract] [Full-text]
  20. Housekeeping genes in prostate tumorigenesis.
    Int J Cancer, 125(11): 2603-8. [Abstract] [Full-text]
  21. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Int J Cancer, 125(11): 2711-20. [Abstract] [Full-text]
  22. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells.
    Int J Cancer, 125(11): 2565-75. [Abstract] [Full-text]
  23. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.
    Int J Cancer, 125(11): 2728-36. [Abstract] [Full-text]
  24. Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters.
    Strahlenther Onkol, 185(10): 689-95. [Abstract] [Full-text]
  25. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.
    Proc Natl Acad Sci U S A, 106(38): 16369-74. [Abstract] [Full-text]
  26. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.
    Proc Natl Acad Sci U S A, 106(38): 16351-6. [Abstract] [Full-text]
  27. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
    Proc Natl Acad Sci U S A, 106(38): 16157-62. [Abstract] [Full-text]
  28. Replication of prostate cancer risk loci in a Japanese case-control association study.
    J Natl Cancer Inst, 101(19): 1330-6. [Abstract] [Full-text]
  29. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    J Natl Cancer Inst, 101(19): 1325-9. [Abstract] [Full-text]
  30. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
    Oncogene, 28(40): 3573-85. [Abstract] [Full-text]
  31. Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins.
    Biochem Biophys Res Commun, 389(3): 455-60. [Abstract] [Full-text]
  32. Prostate specific antigen best practice statement: 2009 update.
    J Urol, 182(5): 2232-41. [Abstract] [Full-text]
  33. The use of a surgical patch in the prevention of lymphoceles after extraperitoneal pelvic lymphadenectomy for prostate cancer: a randomized prospective pilot study.
    J Urol, 182(5): 2285-90. [Abstract] [Full-text]
  34. Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy.
    J Urol, 182(5): 2280-4. [Abstract] [Full-text]
  35. Prostate cancer early detection program recruitment methods and show rates in men at high risk.
    J Urol, 182(5): 2212-7. [Abstract] [Full-text]
  36. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.
    J Urol, 182(5): 2265-72. [Abstract] [Full-text]
  37. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    J Urol, 182(5): 2291-5. [Abstract] [Full-text]
  38. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.
    J Urol, 182(5): 2274-8. [Abstract] [Full-text]
  39. A framework for the identification of men at increased risk for prostate cancer.
    J Urol, 182(5): 2112-20. [Abstract] [Full-text]
  40. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.
    J Urol, 182(5): 2226-31. [Abstract] [Full-text]
  41. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
    J Urol, 182(5): 2242-8. [Abstract] [Full-text]
  42. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    J Urol, 182(5): 2250-5. [Abstract] [Full-text]
  43. Increased low density lipoprotein and increased likelihood of positive prostate biopsy in black americans.
    J Urol, 182(5): 2219-25. [Abstract] [Full-text]
  44. Differing perceptions of quality of life in patients with prostate cancer and their doctors.
    J Urol, 182(5): 2296-302. [Abstract] [Full-text]
  45. Imaging metastatic bone disease from carcinoma of the prostate.
    Br J Cancer, 101(8): 1225-32. [Abstract] [Full-text]
  46. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
    Br J Cancer, 101(8): 1248-52. [Abstract] [Full-text]
  47. DKC1 overexpression associated with prostate cancer progression.
    Br J Cancer, 101(8): 1410-6. [Abstract] [Full-text]
  48. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
    Br J Cancer, 101(8): 1233-40. [Abstract] [Full-text]
  49. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?
    BJU Int, 104(9): 1200-3. [Abstract] [Full-text]
  50. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    BJU Int, 104(9): 1191-7. [Abstract] [Full-text]
  51. The promiscuous receptor.
    BJU Int, 104(9): 1204-7. [Abstract] [Full-text]
  52. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    BJU Int, 104(9): 1215-8. [Abstract] [Full-text]
  53. Differences among patients undergoing perineal or retropubic radical prostatectomy in pain and perioperative variables: a prospective study.
    BJU Int, 104(9): 1219-26. [Abstract] [Full-text]
  54. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    BJU Int, 104(9): 1208-14. [Abstract] [Full-text]
  55. Recovery of erectile function after radical prostatectomy is quantitatively related to the response to intraoperative cavernous nerve stimulation.
    BJU Int, 104(9): 1252-7. [Abstract] [Full-text]
  56. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States.
    Am J Epidemiol, 170(9): 1165-77. [Abstract] [Full-text]
  57. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
    Cancer Immunol Immunother, 59(1): 63-71. [Abstract] [Full-text]
  58. Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract.
    Ann Hematol, 88(12): 1223-8. [Abstract] [Full-text]
  59. Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer.
    Cancer Sci, 100(11): 2109-14. [Abstract] [Full-text]
  60. Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity.
    Cancer Lett, 285(2): 166-73. [Abstract] [Full-text]
  61. Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells.
    Biochem Biophys Res Commun, 390(1): 71-6. [Abstract] [Full-text]
  62. Rethinking screening for breast cancer and prostate cancer.
    JAMA, 302(15): 1685-92. [Abstract] [Full-text]
  63. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.
    J Natl Cancer Inst, 101(20): 1406-11. [Abstract] [Full-text]
  64. Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries.
    BMC Genomics, 10: 476. [Abstract] [Full-text]
  65. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
    Int J Cancer, 125(12): 2836-43. [Abstract] [Full-text]
  66. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.
    Int J Cancer, 125(12): 2871-8. [Abstract] [Full-text]
  67. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
    Int J Cancer, 125(12): 2978-90. [Abstract] [Full-text]
  68. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
    Int J Radiat Oncol Biol Phys, 75(4): 1254-60. [Abstract] [Full-text]
  69. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
    Int J Radiat Oncol Biol Phys, 75(4): 1266-72. [Abstract] [Full-text]
  70. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 994-1002. [Abstract] [Full-text]
  71. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Int J Radiat Oncol Biol Phys, 75(4): 966-74. [Abstract] [Full-text]
  72. Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?
    Int J Radiat Oncol Biol Phys, 75(4): 1008-12. [Abstract] [Full-text]
  73. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
    Int J Radiat Oncol Biol Phys, 75(4): 983-9. [Abstract] [Full-text]
  74. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 975-82. [Abstract] [Full-text]
  75. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 1013-20. [Abstract] [Full-text]
  76. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 1003-7. [Abstract] [Full-text]
  77. Assessing the effect of a contouring protocol on postprostatectomy radiotherapy clinical target volumes and interphysician variation.
    Int J Radiat Oncol Biol Phys, 75(4): 990-3. [Abstract] [Full-text]
  78. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
    Br J Cancer, 101(9): 1620-9. [Abstract] [Full-text]
  79. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
    Prostate, 69(16): 1751-62. [Abstract] [Full-text]
  80. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice.
    Prostate, 69(16): 1763-73. [Abstract] [Full-text]
  81. Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways.
    Prostate, 69(16): 1781-9. [Abstract] [Full-text]
  82. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.
    Prostate, 69(16): 1724-9. [Abstract] [Full-text]
  83. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.
    Prostate, 69(16): 1802-7. [Abstract] [Full-text]
  84. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones.
    Prostate, 69(16): 1744-50. [Abstract] [Full-text]
  85. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.
    Prostate, 69(16): 1730-43. [Abstract] [Full-text]
  86. Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells.
    Am J Physiol Cell Physiol, 297(5): C1188-99. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

American Cancer Society's Complete Guide to Prostate Cancer

American Cancer Society's Complete Guide to Prostate Cancer